TY - JOUR
T1 - Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase
AU - Munir, Shamaila
AU - Larsen, Stine Kiaer
AU - Iversen, Trine Zeeberg
AU - Donia, Marco
AU - Klausen, Tobias Wirenfeldt
AU - Svane, Inge Marie
AU - Straten, Per Thor
AU - Andersen, Mads Hald
PY - 2012/4/23
Y1 - 2012/4/23
N2 - Background: The enzyme indoleamine 2,3-dioxygenase (IDO) contributes to immune tolerance in a variety of settings. In cancer IDO is expressed within the tumor itself as well as in antigen-presenting cells in tumor-draining lymph nodes, where it endorses the establishment of peripheral immune tolerance to tumor antigens. Recently, we described cytotoxic CD8 + T-cell reactivity towards IDO-derived peptides. Methods and Findings: In the present study, we show that CD4 + helper T cells additionally spontaneously recognize IDO. Hence, we scrutinized the vicinity of the previously described HLA-A*0201-restricted IDO-epitope for CD4 + T-cell epitopes. We demonstrated the presence of naturally occurring IDO-specific CD4 + T cells in cancer patients and to a lesser extent in healthy donors by cytokine release ELISPOT. IDO-reactive CD4 + T cells released IFN-γ, TNF-α, as well as IL-17. We confirm HLA class II-restriction by the addition of HLA class II specific blocking antibodies. In addition, we detected a trend between class I- and class II-restricted IDO responses and detected an association between IDO-specific CD4 + T cells and CD8 + CMV-responses. Finally, we could detect IL-10 releasing IDO-reactive CD4 + T cells. Conclusion: IDO is spontaneously recognized by HLA class II-restricted, CD4 + T cells in cancer patients and in healthy individuals. IDO-specific T cells may participate in immune-regulatory networks where the activation of pro-inflammatory IDO-specific CD4 + responses may well overcome or delay the immune suppressive actions of the IDO-protein, which are otherwise a consequence of the early expression of IDO in maturing antigen presenting cells. In contrast, IDO-specific regulatory T cells may enhance IDO-mediated immune suppression.
AB - Background: The enzyme indoleamine 2,3-dioxygenase (IDO) contributes to immune tolerance in a variety of settings. In cancer IDO is expressed within the tumor itself as well as in antigen-presenting cells in tumor-draining lymph nodes, where it endorses the establishment of peripheral immune tolerance to tumor antigens. Recently, we described cytotoxic CD8 + T-cell reactivity towards IDO-derived peptides. Methods and Findings: In the present study, we show that CD4 + helper T cells additionally spontaneously recognize IDO. Hence, we scrutinized the vicinity of the previously described HLA-A*0201-restricted IDO-epitope for CD4 + T-cell epitopes. We demonstrated the presence of naturally occurring IDO-specific CD4 + T cells in cancer patients and to a lesser extent in healthy donors by cytokine release ELISPOT. IDO-reactive CD4 + T cells released IFN-γ, TNF-α, as well as IL-17. We confirm HLA class II-restriction by the addition of HLA class II specific blocking antibodies. In addition, we detected a trend between class I- and class II-restricted IDO responses and detected an association between IDO-specific CD4 + T cells and CD8 + CMV-responses. Finally, we could detect IL-10 releasing IDO-reactive CD4 + T cells. Conclusion: IDO is spontaneously recognized by HLA class II-restricted, CD4 + T cells in cancer patients and in healthy individuals. IDO-specific T cells may participate in immune-regulatory networks where the activation of pro-inflammatory IDO-specific CD4 + responses may well overcome or delay the immune suppressive actions of the IDO-protein, which are otherwise a consequence of the early expression of IDO in maturing antigen presenting cells. In contrast, IDO-specific regulatory T cells may enhance IDO-mediated immune suppression.
U2 - 10.1371/journal.pone.0034568
DO - 10.1371/journal.pone.0034568
M3 - Journal article
SN - 1932-6203
VL - 7
SP - e34568
JO - PLoS Computational Biology
JF - PLoS Computational Biology
IS - 4
ER -
